Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul>
<li>Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and challenges within the business and market environment.</li>
<li>The company's results reflect a dynamic phase of development across its RNAi-based therapeutics pipeline, milestones in partnerships, and forward momentum in commercialization efforts.</li>
<li>Here is an analysis of the quarter's outcomes, presented in a balanced manner.</li>
</ul>


Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and challenges within the business and market environment.
The company's results reflect a dynamic phase of development across its RNAi-based therapeutics pipeline, milestones in partnerships, and forward momentum in commercialization efforts.
Here is an analysis of the quarter's outcomes, presented in a balanced manner.


Arrowhead Pharmaceuticals: Therapeutic Advancements in FCS & SHTG...

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.</li>
<li>In terms of quantity and quality of innovations <a href="https://www.smartkarma.com/entities/alnylam-pharmaceuticals-inc" target="_blank" data-smartkarma-citation="entities:2191:1" rel="noopener">Alnylam Pharmaceuticals (ALNY US)</a>  and <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna (MRNA US)</a>  are best positioned. Among private companies Senda Biosciences screened well. </li>
<li>Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.</li>
</ul>


In this report we analyzed data from technical publications to review leadership in RNA related therapeutics. We have listed the top thirty.
In terms of quantity and quality of innovations Alnylam Pharmaceuticals (ALNY US)  and Moderna (MRNA US)  are best positioned. Among private companies Senda Biosciences screened well. 
Partnerships and acquisitions  between RNA startups and big pharma as well as between big pharma and big pharma highlight RNA's potential versatility, risks and the necessity for RNA related exposure.


Who Are Leading the Charge in the RNAissance of Medicine

<ul>
<li>Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial strategies, suggesting a pivotal phase in its growth trajectory.</li>
<li>As the pharmaceutical company aims to augment its pipeline to include around 20 clinical or marketed products by 2025, it focuses heavily on the development and potential market launch of its flagship product, plozasiran, targeting familial chylomicronemia syndrome (FCS) and other conditions associated with high triglycerides.</li>
<li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li>
</ul>


Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial strategies, suggesting a pivotal phase in its growth trajectory.
As the pharmaceutical company aims to augment its pipeline to include around 20 clinical or marketed products by 2025, it focuses heavily on the development and potential market launch of its flagship product, plozasiran, targeting familial chylomicronemia syndrome (FCS) and other conditions associated with high triglycerides.
Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.


Arrowhead Pharmaceuticals: Expanding Clinical Trials & Regulatory Approvals!

<ul>
<li>Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024.</li>
<li>A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities.</li>
<li>In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders.</li>
</ul>


Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March 31, 2024.
A major focus for the company during this period has been its expanding presence in the cardiometabolic space, where substantial investments have been channeled to advance clinical and pre-commercial activities.
In these endeavors, significant strides were made with plozasiran and zodasiran, their leading drug candidates designed to tackle diseases associated with lipid disorders.


Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!

<ul>
<li>Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a minimum of 20 clinical-stage or marketed products by the year 2025.</li>
<li>This pledge reflects Arrowhead's two core goals of maximizing the number of patients aided and the ability to generate enduring value for shareholders.</li>
<li>Due to the company's maturing pipeline, Arrowhead is focusing on prioritizing and investing in their internal programs and is actively building late-stage development and commercial infrastructure to focus on the cardiometabolic vertical.</li>
</ul>


Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a minimum of 20 clinical-stage or marketed products by the year 2025.
This pledge reflects Arrowhead's two core goals of maximizing the number of patients aided and the ability to generate enduring value for shareholders.
Due to the company's maturing pipeline, Arrowhead is focusing on prioritizing and investing in their internal programs and is actively building late-stage development and commercial infrastructure to focus on the cardiometabolic vertical.


Arrowhead Pharmaceuticals: Progression of ARO-MUC5AC & ARO-MMP7 Programs & Other Major Drivers

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arrowhead Pharmaceuticals (ARWR US)

Arrowhead Pharmaceuticals: Therapeutic Advancements in FCS & SHTG...

Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and...

Baptista Research

Who Are Leading the Charge in the RNAissance of Medicine

RNA therapeutics: We analyze the field and spotlight top players driving this precision medicine, for tackling rare diseases with innovative solutions

Pyari Menon

Arrowhead Pharmaceuticals: Expanding Clinical Trials & Regulatory Approvals!

Arrowhead Pharmaceuticals recently discussed its fiscal 2024 third-quarter performance and provided updates on its drug pipeline and commercial...

Baptista Research

Arrowhead Pharmaceuticals: Expansion of TRiM Platform and Entry into New Therapeutic Areas!

Arrowhead Pharmaceuticals delivered a comprehensive update on its operational and financial developments for the fiscal second quarter ended March...

Baptista Research

Arrowhead Pharmaceuticals: Progression of ARO-MUC5AC & ARO-MMP7 Programs & Other Major Drivers

Arrowhead Pharmaceuticals is committed to rapidly innovating and developing treatments and plans to grow their pipeline of RNAi therapeutics to a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)